SCHEMBL2664702

SCHEMBL2664702

CNc1cc(OCc2ccccc2Cl)cc(C(=O)Nc2ncc(C(=O)O)s2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 6/20 0.52
CSNK2A1 P68400 6/20 0.52
GCK P35557 2/20 0.49
NR4A2 P43354 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
LCK P06239 1/20 0.46
ABL1 P00519 1/20 0.43
MAPT P10636 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
SCD O00767 1/20 0.42
RARA P10276 1/20 0.42
RARB P10826 1/20 0.42
RARG P13631 1/20 0.42
POLB P06746 1/20 0.42
MAPK13 O15264 1/20 0.41
MAPK12 P53778 1/20 0.41
MAPK11 Q15759 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1796180 0.92 CSNK2A2 (0.55) CSNK2A2CSNK2A1GCKNR4A2NPC1
SCHEMBL1792159 0.81 CSNK2A2 (0.49) CSNK2A2CSNK2A1GCKNR4A2NPC1
SCHEMBL1798143 0.81 CSNK2A2 (0.47) CSNK2A2CSNK2A1GCKLCKMAPT
SCHEMBL2664730 0.80 GCK (0.65) CSNK2A2CSNK2A1GCKABL1SCD
SCHEMBL2664690 0.78 GCK (0.61) CSNK2A2CSNK2A1GCKNR4A2NPC1
SCHEMBL2664711 0.78 GCK (0.53) CSNK2A2CSNK2A1GCKNPC1RAB9A
SCHEMBL2664760 0.78 CSNK2A2 (0.60) CSNK2A2CSNK2A1GCKABL1MAPT
SCHEMBL2664733 0.76 CSNK2A2 (0.61) CSNK2A2CSNK2A1MAPK13MAPK12MAPK11
SCHEMBL2664744 0.76 GCK (0.46) CSNK2A2CSNK2A1GCKLCKSCD
SCHEMBL2664694 0.76 GRM4 (0.53) CSNK2A2CSNK2A1GCKNR4A2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951830-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2011-05-31 US disclosed
US-7951830-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2011-05-31 US disclosed
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE ASTRAZENECA AB (SE) 2009-09-10 US disclosed
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE ASTRAZENECA AB (SE) 2009-09-10 US disclosed
US-7524957-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2009-04-28 US disclosed
US-20080207636-A1 Compounds Effecting Glucokinase ASTRAZENECA AB (SE) 2008-08-28 US disclosed
US-7390908-B2 Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes ASTRAZENECA AB (SE) 2008-06-24 US disclosed
US-7390908-B2 Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes ASTRAZENECA AB (SE) 2008-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207636-A1 Compounds Effecting Glucokinase GCKR, GCK, SLC5A2 CSNK2A2 444/4885CSNK2A1 432/4885GCK 2/4885
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE GCKR, GCK, SLC5A2 CSNK2A2 444/4885CSNK2A1 432/4885GCK 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.